Skip to main content

Capvaxive News

CDC Lowers Age for First Pneumococcal Vaccine to 50

THURSDAY, Oct. 24, 2024 – The recommended first age at which Americans should get the pneumococcal vaccine has been lowered from 65 to 50, the U.S. Centers for Disease Control and Prevention...

FDA Approves Capvaxive (pneumococcal 21-valent conjugate vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Capvaxive patient information at Drugs.com